{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:24:02Z","timestamp":1787243042344,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"provincial natural science foundation project","award":["No.24JRRA767"],"award-info":[{"award-number":["No.24JRRA767"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01347-0","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:18:58Z","timestamp":1765610338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Different Treatment Regimens for Previously Untreated Patients with HER2-positive Advanced Gastric Cancer: A Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"56","author":[{"given":"Yuqi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"1347_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152692","volume":"16","author":"M Ratti","year":"2024","unstructured":"Ratti M, et al. Emerging therapeutic targets and future directions in advanced gastric cancer: a comprehensive review. Cancers (Basel). 2024;16:2692. https:\/\/doi.org\/10.3390\/cancers16152692.","journal-title":"Cancers (Basel)"},{"key":"1347_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1327055","volume":"14","author":"H Li","year":"2024","unstructured":"Li H, et al. Current therapies and progress in the treatment of advanced gastric cancer. Front Oncol. 2024;14:1327055. https:\/\/doi.org\/10.3389\/fonc.2024.1327055.","journal-title":"Front Oncol"},{"key":"1347_CR3","doi-asserted-by":"publisher","unstructured":"Jiang Y-K, et al. Advances in targeted therapy for human epidermal growth factor receptor 2 positive in advanced gastric cancer. World J Gastrointest Oncol. 2024(6). https:\/\/doi.org\/10.4251\/wjgo.v16.i6.2318.","DOI":"10.4251\/wjgo.v16.i6.2318"},{"key":"1347_CR4","doi-asserted-by":"publisher","unstructured":"Wang W, et al. A functional polymorphism in TFF1 promoter is associated with the risk and prognosis of gastric cancer. Int J Cancer. 2018(9). https:\/\/doi.org\/10.1002\/ijc.31197.","DOI":"10.1002\/ijc.31197"},{"key":"1347_CR5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/annonc\/mdx051","volume":"8","author":"F Lordick","year":"2017","unstructured":"Lordick F, et al. New agents on the horizon in gastric cancer. Annals Oncology: Official J Eur Soc Med Oncol. 2017;8:1767\u201375. https:\/\/doi.org\/10.1093\/annonc\/mdx051.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"1347_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/ijo.2024.5624","volume":"4","author":"H-H Hu","year":"2024","unstructured":"Hu H-H, et al. HER2+ advanced gastric cancer: current state and opportunities. (Review) Int J Oncol. 2024;4:36. https:\/\/doi.org\/10.3892\/ijo.2024.5624.","journal-title":"(Review) Int J Oncol"},{"key":"1347_CR7","doi-asserted-by":"publisher","unstructured":"Aoki M, et al. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Gastric Cancer. 2021(3). https:\/\/doi.org\/10.1007\/s10120-021-01164-x.","DOI":"10.1007\/s10120-021-01164-x"},{"issue":"34","key":"1347_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029992","volume":"101","author":"C Xue","year":"2022","unstructured":"Xue C, Xu Y-H. Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: a systematic review and meta-analysis of randomized controlled trial. Medicine (Baltimore). 2022;(34):e29992. https:\/\/doi.org\/10.1097\/MD.0000000000029992.","journal-title":"Medicine (Baltimore)"},{"key":"1347_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1476402","volume":"15","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study. Front Oncol. 2025;1476402. https:\/\/doi.org\/10.3389\/fonc.2025.1476402.","journal-title":"Front Oncol"},{"key":"1347_CR10","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1097\/MS9.0000000000002305","volume":"8","author":"Z Qureshi","year":"2012","unstructured":"Qureshi Z, et al. Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer. Annals Med Surg. 2012;8:4647\u201356. https:\/\/doi.org\/10.1097\/MS9.0000000000002305.","journal-title":"Annals Med Surg"},{"key":"1347_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24426-9","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu S, et al. Comparative efficacy and tolerability of targeted and immunotherapy combined with chemotherapy as first-line treatment for advanced gastric cancer: a bayesian network meta-analysis. Sci Rep. 2022;12:22024. https:\/\/doi.org\/10.1038\/s41598-022-24426-9.","journal-title":"Sci Rep"},{"key":"1347_CR12","doi-asserted-by":"publisher","unstructured":"Cumpston MS et al. (2022) Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. Journal of public health (Oxford, England) 4: e588-e592. https:\/\/doi.org\/10.1093\/pubmed\/fdac036","DOI":"10.1093\/pubmed\/fdac036"},{"key":"1347_CR13","doi-asserted-by":"crossref","unstructured":"Tintelnot J, et al. Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. J Clin Oncol. 2023 41.16-Sup:1.","DOI":"10.1200\/JCO.2023.41.16_suppl.4026"},{"key":"1347_CR14","unstructured":"Randolph J, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-Positive advanced or metastatic Gastric, Esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC\u2013A randomized phase III Trial. Journal of clinical oncology. official journal of the American Society of Clinical Oncology; 2016."},{"key":"1347_CR15","doi-asserted-by":"crossref","unstructured":"Shitara K et al. (2019) Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial.International. J Clin Oncol 25.2.","DOI":"10.1007\/s10147-019-01558-z"},{"issue":"17","key":"1347_CR16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03077","volume":"38","author":"A Makiyama","year":"2020","unstructured":"Makiyama A, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol. 2020;38(17):JCO.19.03077.","journal-title":"J Clin Oncol"},{"key":"1347_CR17","first-page":"1150","volume":"8","author":"A Stein","year":"2022","unstructured":"Stein A, et al. Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-Positive esophagogastric adenocarcinoma: the AIO INTEGA randomized clinical trial. JAMA Oncol. 2022;8:1150\u20138.","journal-title":"JAMA Oncol"},{"key":"1347_CR18","doi-asserted-by":"publisher","unstructured":"Kong Y, et al. Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. World J Gastroenterol. 2024(40). https:\/\/doi.org\/10.3748\/wjg.v30.i40.4367.","DOI":"10.3748\/wjg.v30.i40.4367"},{"key":"1347_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10120-022-01335-4","volume":"1","author":"J Tabernero","year":"2023","unstructured":"Tabernero J, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric\/gastroesophageal junction cancer: end-of-study analysis of the JACOB phaseiii randomized clinical trial. Gastric Cancer. 2023;1:123\u201331.","journal-title":"Gastric Cancer"},{"key":"1347_CR20","unstructured":"Josep, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncology; 2018."},{"issue":"10418","key":"1347_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0","volume":"402","author":"YelenaY Janjigian","year":"2023","unstructured":"Janjigian Yelena Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):12.","journal-title":"Lancet"},{"key":"1347_CR22","doi-asserted-by":"publisher","unstructured":"Li N et al. (2024) A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer.Med (New York, N.Y.) 10: 1255\u2013e12652. https:\/\/doi.org\/10.1016\/j.medj.2024.06.004","DOI":"10.1016\/j.medj.2024.06.004"},{"key":"1347_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1560280","volume":"16","author":"Q Shao","year":"2025","unstructured":"Shao Q, et al. HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy. Front Immunol. 2025;16:1560280. https:\/\/doi.org\/10.3389\/fimmu.2025.1560280.","journal-title":"Front Immunol"},{"key":"1347_CR24","doi-asserted-by":"publisher","unstructured":"Gall Victor A, et al. Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells. Cancer Res. 2017(19). https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2774.","DOI":"10.1158\/0008-5472.CAN-16-2774"},{"key":"1347_CR25","doi-asserted-by":"publisher","unstructured":"Janjigian Yelena Y, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020(6). https:\/\/doi.org\/10.1016\/S1470-2045(20)30169-8.","DOI":"10.1016\/S1470-2045(20)30169-8"},{"key":"1347_CR26","doi-asserted-by":"publisher","unstructured":"Ariga S. (2024) History and future of HER2-Targeted therapy for advanced gastric Cancer.Journal of clinical medicine 12,10 3391. https:\/\/doi.org\/10.3390\/jcm12103391","DOI":"10.3390\/jcm12103391"},{"key":"1347_CR27","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.medj.2024.06.004","volume":"10","author":"N Li","year":"2024","unstructured":"Li N, et al. A randomized phase 2 study of HLX22 plus trastuzumab biosimilar HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric cancer. Med. 2024;10:1255\u2013e12652. https:\/\/doi.org\/10.1016\/j.medj.2024.06.004.","journal-title":"Med"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01347-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01347-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T07:18:59Z","timestamp":1765610339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01347-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01347-0","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"1 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"239"}}